Advanced Neurosciences Research — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2023	Research	$141,615	8
2022	Research	$43,749	6
2021	Research	$52,025	15
2020	Research	$115,059	12
2019	Research	$216,199	10

Breakdown

Who paid Research payments · program years 2019–2023

Novartis Pharmaceuticals Corporation $280,728 8 payments
Genentech, Inc. $141,615 8 payments
Allergan Inc. $139,620 29 payments
Adamas Pharmaceuticals, Inc. $6,684 6 payments

Studies the money was for Research payments · program years 2019–2023

Exploring the Safety and Tolerability of Conversion to Dose Titrated Siponimod in Patients With Relapsing Forms of Multiple Sclerosis A 6 Month Open Label Multi Center Phase III B Study Expanded $244,652 4 payments
Ensemble $141,615 8 payments
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Treatment of Migraine When Adminstered During the Premonitory Phase $66,346 11 payments
A Phase 3, Multicenter, Randomized, Open-Label Study to Evaluate the Longterm Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Patients With Episodic Migraine $63,898 15 payments
A Randomized Double Blind Double Dummy Parallel Group Study Comparing the Efficacy and Safety of Ofatumumab Administered Subcutaneously Versus Teriflunomide Administered Orally in Patients With Relapsing Forms of Multiple Sclerosis $31,074 2 payments
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Treatment of Migraine When Adminstered During the Premonitory Phase $9,376 3 payments
A Multicenter Open-Label Safety and Efficacy Study of Ads-5102 Amantadine Extended Release Capsules in Patients With Multiple Sclerosis and Walking Impairment $6,684 6 payments
An Open Label Single Arm Multi Center Extension Study Evaluating Long Term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis $4,854 1 payment
An Open Label Study to Assess Response to Influenza Vaccine in Ofatumumab Treated Patients. $149 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.